MSLN and neoplasm: The development of mesothelin-specific CD8+ T-cell immunity seems being a useful marker to predict a successful tumor protection as previous studies testing multiple immunotherapeutics in animals and humans also show a positive parallel between antitumor efficacy and mesothelin-specific CD8+ T-cell immunity [25, 26, 29, 38, 39].